Medtronic PLC $MDT Shares Acquired by Gradient Investments LLC

Gradient Investments LLC lifted its holdings in shares of Medtronic PLC (NYSE:MDT) by 3.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 479,133 shares of the medical technology company’s stock after acquiring an additional 15,870 shares during the quarter. Gradient Investments LLC’s holdings in Medtronic were worth $46,026,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Delos Wealth Advisors LLC purchased a new position in Medtronic during the second quarter worth about $27,000. Corundum Trust Company INC acquired a new stake in shares of Medtronic during the third quarter valued at about $27,000. Valley Wealth Managers Inc. purchased a new stake in shares of Medtronic in the 3rd quarter valued at approximately $29,000. Board of the Pension Protection Fund acquired a new position in shares of Medtronic in the 4th quarter worth approximately $29,000. Finally, GoalVest Advisory LLC acquired a new position in shares of Medtronic in the 4th quarter worth approximately $29,000. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Price Performance

Medtronic stock opened at $86.29 on Monday. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33. The firm has a market cap of $110.78 billion, a PE ratio of 24.03, a price-to-earnings-growth ratio of 2.21 and a beta of 0.71. The company’s 50 day moving average is $96.82 and its two-hundred day moving average is $96.72.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same quarter in the previous year, the firm posted $1.38 earnings per share. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be issued a dividend of $0.71 per share. The ex-dividend date is Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.3%. Medtronic’s dividend payout ratio is 79.11%.

Insiders Place Their Bets

In related news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.26% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

MDT has been the subject of several research reports. Barclays reiterated an “overweight” rating and issued a $118.00 target price on shares of Medtronic in a report on Wednesday, February 18th. Daiwa Securities Group decreased their price target on Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. JPMorgan Chase & Co. dropped their price objective on Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th. Mizuho upgraded Medtronic to a “strong-buy” rating in a report on Wednesday, February 18th. Finally, CICC Research began coverage on Medtronic in a research note on Friday, January 30th. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.74.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).